Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung

DRUG4 trials

Sponsors

Institut fuer Klinische Krebsforschung IKF GmbH, F. Hoffmann-La Roche AG, AGO Research GmbH

Conditions

Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)Completely resectedPancreatic ductal adenocarcinoma (PDAC)Stage Ib (tumors ≥ 4 cm) to Stage IIIaThis trial evaluates the efficacy and safety of Mirvetuximab soravtansine (IMGN853) plus Carboplatin chemotherapy in FRα high patients with recurrent ovarian cancer who are eligible for platinum-based chemotherapy.cholangiocarcinoma or gallbladder carcinoma

Phase 1

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus–Pancreatic Cancer)

CompletedCTIS2024-511271-15-00

F. Hoffmann-La Roche AGPancreatic ductal adenocarcinoma (PDAC)

Start: 2017-11-23End: 2025-02-07Target: 29Updated: 2024-04-04

Phase 2

TRAP-BTC Efficacy and safety of GemCis plus Trastuzumab plus Pembrolizumab in previously untreated HER2-positive biliary tract cancer

RecruitingCTIS2023-505722-33-00

Institut fuer Klinische Krebsforschung IKF GmbHcholangiocarcinoma or gallbladder carcinoma

Start: 2024-04-15Target: 24Updated: 2026-01-22

A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy. supported by: DIAGNOSTIC PROTOCOL for the VENTANA FOLR1 (FOLR1-2.1) CDx Assay Ventana No. RD004881; Protocol Document No. D152967

Active, not recruitingCTIS2024-516959-40-00

AGO Research GmbHThis trial evaluates the efficacy and safety of Mirvetuximab soravtansine (IMGN853) plus Carboplatin chemotherapy in FRα high patients with recurrent ovarian cancer who are eligible for platinum-based chemotherapy.

Start: 2021-08-17Target: 136Updated: 2025-12-05

Phase 3

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients with Completely Resected Stage Ib (Tumors ≥ 4 Cm) to Stage IIIa Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer

Active, not recruitingCTIS2023-506861-76-00

F. Hoffmann-La Roche AGAnaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC), Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa

Start: 2018-08-09Target: 55Updated: 2025-05-26